Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases
Abstract Background Clinical progression of HBV-related liver diseases is largely associated with the activity of HBV-specific T cells. Soluble fibrinogen-like protein 2 (sFGL2), mainly secreted by T cells, is an important effector molecule of the immune system. Methods sFGL2 levels were determined by ELISA assays in sera of 296 HBV patients clinically classified into the subgroups of acute hepatitis B (AHB), chronic hepatitis B (CHB), liver cirrhosis (LC), hepatocellular carcinoma (HCC) and patients with LC plus HCC. As control group, 158 healthy individuals were included. FGL2 mRNA was quantified by qRT-PCR in 32 pairs of tumor and adjacent non-tumor liver tissues. Results sFGL2 levels were elevated in HBV patients compared to healthy controls (P < 0.0001). In the patient group, sFGL2 levels were increased in AHB compared to CHB patients (P = 0.017). sFGL2 levels were higher in LC patients compared to those without LC (P = 0.006) and were increased according to the development of cirrhosis as staged by Child-Pugh scores (P = 0.024). Similarly, HCC patients had increased sFGL2 levels compared to CHB patients (P = 0.033) and FGL2 mRNA was up-regulated in tumor tissues compared to adjacent non-tumor tissues (P = 0.043). In addition, sFGL2 levels were positively correlated with HBV-DNA loads and AST (Spearman’s rho = 0.21, 0.25 and P = 0.006, 0.023, respectively), but reversely correlated with platelet counts and albumin levels (Spearman’s rho = − 0.27, − 0.24 and P = 0.014, 0.033, respectively). Conclusions sFGL2 levels are induced by HBV infection and correlated with the progression and clinical outcome of HBV-related liver diseases. Thus, sFGL2 may serve as a potential indicator for HBV-related liver diseases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
BMC Infectious Diseases - 18(2018), 1, Seite 9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hoang Van Tong [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
HBV infection |
|---|
| doi: |
10.1186/s12879-018-3473-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ059636440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ059636440 | ||
| 003 | DE-627 | ||
| 005 | 20230503102357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-018-3473-2 |2 doi | |
| 035 | |a (DE-627)DOAJ059636440 | ||
| 035 | |a (DE-599)DOAJbeb4b5b629b042e7a911f60686a3a526 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Hoang Van Tong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Clinical progression of HBV-related liver diseases is largely associated with the activity of HBV-specific T cells. Soluble fibrinogen-like protein 2 (sFGL2), mainly secreted by T cells, is an important effector molecule of the immune system. Methods sFGL2 levels were determined by ELISA assays in sera of 296 HBV patients clinically classified into the subgroups of acute hepatitis B (AHB), chronic hepatitis B (CHB), liver cirrhosis (LC), hepatocellular carcinoma (HCC) and patients with LC plus HCC. As control group, 158 healthy individuals were included. FGL2 mRNA was quantified by qRT-PCR in 32 pairs of tumor and adjacent non-tumor liver tissues. Results sFGL2 levels were elevated in HBV patients compared to healthy controls (P < 0.0001). In the patient group, sFGL2 levels were increased in AHB compared to CHB patients (P = 0.017). sFGL2 levels were higher in LC patients compared to those without LC (P = 0.006) and were increased according to the development of cirrhosis as staged by Child-Pugh scores (P = 0.024). Similarly, HCC patients had increased sFGL2 levels compared to CHB patients (P = 0.033) and FGL2 mRNA was up-regulated in tumor tissues compared to adjacent non-tumor tissues (P = 0.043). In addition, sFGL2 levels were positively correlated with HBV-DNA loads and AST (Spearman’s rho = 0.21, 0.25 and P = 0.006, 0.023, respectively), but reversely correlated with platelet counts and albumin levels (Spearman’s rho = − 0.27, − 0.24 and P = 0.014, 0.033, respectively). Conclusions sFGL2 levels are induced by HBV infection and correlated with the progression and clinical outcome of HBV-related liver diseases. Thus, sFGL2 may serve as a potential indicator for HBV-related liver diseases. | ||
| 650 | 4 | |a sFGL2 levels | |
| 650 | 4 | |a HBV infection | |
| 650 | 4 | |a Viral hepatitis | |
| 650 | 4 | |a Liver cirrhosis | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Nguyen Van Ba |e verfasserin |4 aut | |
| 700 | 0 | |a Nghiem Xuan Hoan |e verfasserin |4 aut | |
| 700 | 0 | |a Mai Thanh Binh |e verfasserin |4 aut | |
| 700 | 0 | |a Dao Thanh Quyen |e verfasserin |4 aut | |
| 700 | 0 | |a Ho Anh Son |e verfasserin |4 aut | |
| 700 | 0 | |a Hoang Van Luong |e verfasserin |4 aut | |
| 700 | 0 | |a Do Quyet |e verfasserin |4 aut | |
| 700 | 0 | |a Christian G. Meyer |e verfasserin |4 aut | |
| 700 | 0 | |a Le Huu Song |e verfasserin |4 aut | |
| 700 | 0 | |a Nguyen Linh Toan |e verfasserin |4 aut | |
| 700 | 0 | |a Thirumalaisamy P. Velavan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t BMC Infectious Diseases |d BMC, 2003 |g 18(2018), 1, Seite 9 |w (DE-627)DOAJ000056693 |x 14712334 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:1 |g pages:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-018-3473-2 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/beb4b5b629b042e7a911f60686a3a526 |z kostenfrei |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1186/s12879-018-3473-2 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1471-2334 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 1 |h 9 | ||